Tango Therapeutics, Inc.
TNGX
Classifica tra le azioni
#4540
Tango Therapeutics, Inc. is a biotechnology firm dedicated to the research and... Tango Therapeutics, Inc. is a biotechnology firm dedicated to the research and development of innovative cancer treatments. Their primary therapeutic candidate, TNG908, is a synthetic lethal small molecule designed to inhibit protein arginine methyltransferase 5 (PRMT5). This compound is currently being advanced as a potential therapy for cancers characterized by methylthioadenosine phosphorylase (MTAP) deletions. Additionally, their pipeline includes an Ubiquitin-specific protease 1 (USP1) inhibitor targeting BRCA1 or BRCA2-mutant cancers, and a program known as 'Target 3' which addresses STK11-mutant cancers. Tango Therapeutics maintains a strategic alliance with Gilead Sciences, Inc., focused on the identification, advancement, and commercialization of a diverse array of cancer therapies. Established in 2017, the company's operations are headquartered in Cambridge, Massachusetts.
Prezzo delle azioni
$27.18
Ultima sincronizzazione: 2026-07-31
Capitalizzazione di mercato
$3.38B
Variazione (1 giorno)
-1.41%
Variazione (1 anno)
202.34%
Paese
US
Scambia Tango Therapeutics, Inc. (TNGX)
Categoria
Healthcare
Utile per Tango Therapeutics, Inc. (TNGX)
Utile nel Jun 2026 TTM: $-123.78M
Secondo gli ultimi rapporti finanziari di Tango Therapeutics, Inc., gli utili attuali della società sono $-123.78M. Nel 2023, la società ha registrato un utile di $-101.61M, un aumento rispetto a agli utili del 2022, che erano di $-108.12M. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Storico degli utili di Tango Therapeutics, Inc. dal 2019 al 2026
Utile alla fine di ogni anno
| Anno | Utile | Cambia |
|---|---|---|
| 2026 (TTM) | $-123.78M | -4.85% |
| 2024 | $-130.09M | 28.03% |
| 2023 | $-101.61M | -6.02% |
| 2022 | $-108.12M | 86.60% |
| 2021 | $-57.94M | 11.49% |
| 2020 | $-51.97M | 268.73% |
| 2019 | $-14.10M | 0.00% |
Utile per aziende simili o concorrenti
| Azienda | Utile | Differenza negli utili | Il paese |
|---|---|---|---|
| $5.27B | -4,361.41% |
US
|
|
| $-3.09B | 2,393.88% |
US
|
|
| $-4.02B | 3,144.55% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | -1,675.86% |
NL
|
